Institutional members access full text with Ovid®

Multidrug-experienced HIV-1-infected women demonstrated similar virological and immunological responses to tipranavir/ritonavir compared with men

Walmsley, Sharon La; Squires, Kathleenb; Weiss, Laurencec; Easterbrook, Philippad; Orani, Annae; Kraft, Michaelf; Scherer, Josephf

doi: 10.1097/QAD.0b013e3283229f81
Research Letters

Gender-related differences in the efficacy and safety of ritonavir-boosted tipranavir [tipranavir/ritonavir (TPV/r) 500/200 mg twice daily (b.i.d.)] were evaluated in a subanalysis of the Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients with Tipranavir (RESIST) trials. Data from HIV-1-infected women (203; TPV/r = 117) and men (1280; TPV/r = 629) showed no significant gender-related differences in HIV RNA response rates (at 48 weeks) and safety (at 96 weeks) despite higher mean steady-state plasma TPV trough concentrations in women. Significantly greater increases in CD4 cell count (+81.2 vs. +48.6; P = 0.0012) were observed in women at week 48.

aUniversity Health Network, University of Toronto, Toronto, Canada

bJefferson Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania, USA

cUniversité Paris Descartes, Faculté de Médecine; AP-HP, Hôpital Européen Georges Pompidou, Paris, France

dKing's College Hospital, London, UK

eClinica di Malattie Infective, Lecco, Italy

fBoehringer Ingelheim, Ingelheim, Germany.

Received 8 October, 2008

Accepted 27 October, 2008

Correspondence to Sharon Walmsley, Professor of Medicine, University Health Network, Eaton North Wing, 13th floor Rm. 218, 200 Elizabeth Street, Toronto, Ontario, Canada M5G 2C4. E-mail:

© 2009 Lippincott Williams & Wilkins, Inc.